Kurzgefasstes exegetisches Handbuch zum Neuen Testament /

In 11 parts; each part has general and special title page.

The Bible-work, the Old Testament; the revised text, arranged in sections; with comments selected from the choicest, most illuminating and helpful thoughts of the christian centuries, taken from four hundred scholarly writers.

Vol. I. Genesis chap. I. to Exodus chap. XII.--Vol.II. Exodus (chap. XII), Leviticus, Numbers and Deuteronomy.--Vol. III. Joshua, Judges, Ruth, 1st and 2nd Samuel, 1 Chronicles XI., 1 Kings I-XI., 2 Chronicles I-IX.

Hand-commentar zum Neuen Testament /

1. Bd. Die Synoptiker - Die Apostelgeschichte, von H.J. Holtzmann -- 2. Bd. , 1 Abt. Die Briefe an die Thessalonicher und an die Korinther, von P.W. Schmiedel. 2. Abt. Briefe an die Galater, Römer, Philipper, von R.A. Lipsius -- 3. Bd. , 1 Abt. Die Briefe an die Kolosser, Epheser, Philemon. Die Pastoralbriefe. 2. Abt. Der Hebräerbrief. Die Briefe des Petrus, Jakobus, Judas, von H. von Soden -- 4. Bd. Evangelius, Briefe und Offenbarung des Johannes, von H.J. Holtzmann.

Exposition of the Old and New Testament : wherein each chapter is summed up in its contents : the sacred text inserted at large, in distinct paragaraphs : each paragraph reduced to its proper heads : the sense given, and largely illustrated : with practical remarks ad observations /

This edition not illustrated.

Illustrations of the Holy Scriptures : in three parts. I. From the geography of the East. II. From the natural history of the East. III From the customs of ancient and modern nations /

"An introduction to the geography of the New Testament ... by Lant Carpenter. Philadelphia : J. Anderson, printer, 1822" has special t.p. and separate paging.

The Bible-work : (or Bible Reader's Commentary). The New Testament, in two volumes /

v.I. The fourfold Gospel.--v. II. The Acts, the Epistles and the Revelation.

Le Nouveau Testament de Notre Seigneur Jésus-Christ /

Mode of access: Internet.

Leitfaden zum unterricht im Alten Testament, für höhere schulen /

Mode of access: Internet.

The Old Testament in Greek, according to the Septuagint /

v. 1. Genesis-IV King -- v. 2. I. Chronicles-Tobit -- v. 3. Hosea-4 Maccabees, Psalms of Solomon, Enoch, The Odes.

The Old Testament in Greek according to the Septuagint /

Commonly known as the "smaller" or "shorter" Cambridge Septuagint.

An exposition of the Old and New Testament ... /

T. P.'s for v. 5-6 varies : "New edition ... " [without note as to preface by Archibald Alexander]

Die Aramaismen im Alten Testament untersucht /

Osterprogramm--Halle, 1901-02.

R&D&I Tax Incentives in the European Union and State Aid Rules

Although tax incentives are an effective tool for promoting R&D&I, depending on their design they may qualify as State aid (article 107(1) of the TFEU) unless exempted by the Commission (article 107(3)). This article discusses the role of State aid rules in respect of R&D&I incentives and the need to ensure R&D&I promotion policies in Europe are on equal footing with the rest of the world, thus ensuring a level playing field for European undertakings in global markets.

An Isoflavone From Dipteryx Alata Vogel Is Active Against The In Vitro Neuromuscular Paralysis Of Bothrops Jararacussu Snake Venom And Bothropstoxin I, And Prevents Venom-induced Myonecrosis.

Snakebite is a neglected disease and serious health problem in Brazil, with most bites being caused by snakes of the genus Bothrops. Although serum therapy is the primary treatment for systemic envenomation, it is generally ineffective in neutralizing the local effects of these venoms. In this work, we examined the ability of 7,8,3'-trihydroxy-4'-methoxyisoflavone (TM), an isoflavone from Dipteryx alata, to neutralize the neurotoxicity (in mouse phrenic nerve-diaphragm preparations) and myotoxicity (assessed by light microscopy) of Bothrops jararacussu snake venom in vitro. The toxicity of TM was assessed using the Salmonella microsome assay (Ames test). Incubation with TM alone (200 μg/mL) did not alter the muscle twitch tension whereas incubation with venom (40 μg/mL) caused irreversible paralysis. Preincubation of TM (200 μg/mL) with venom attenuated the venom-induced neuromuscular blockade by 84% ± 5% (mean ± SEM; n = 4). The neuromuscular blockade caused by bothropstoxin-I (BthTX-I), the major myotoxic PLA2 of this venom, was also attenuated by TM. Histological analysis of diaphragm muscle incubated with TM showed that most fibers were preserved (only 9.2% ± 1.7% were damaged; n = 4) compared to venom alone (50.3% ± 5.4% of fibers damaged; n = 3), and preincubation of TM with venom significantly attenuated the venom-induced damage (only 17% ± 3.4% of fibers damaged; n = 3; p < 0.05 compared to venom alone). TM showed no mutagenicity in the Ames test using Salmonella strains TA98 and TA97a with (+S9) and without (-S9) metabolic activation. These findings indicate that TM is a potentially useful compound for antagonizing the neuromuscular effects (neurotoxicity and myotoxicity) of B. jararacussu venom.

Nebivolol Reduces Central Blood Pressure In Stage I Hypertensive Patients: Experimental Single Cohort Study.

Assessment of central blood pressure (BP) has grown substantially over recent years because evidence has shown that central BP is more relevant to cardiovascular outcomes than peripheral BP. Thus, different classes of antihypertensive drugs have different effects on central BP despite similar reductions in brachial BP. The aim of this study was to investigate the effect of nebivolol, a β-blocker with vasodilator properties, on the biochemical and hemodynamic parameters of hypertensive patients. Experimental single cohort study conducted in the outpatient clinic of a university hospital. Twenty-six patients were recruited. All of them underwent biochemical and hemodynamic evaluation (BP, heart rate (HR), central BP and augmentation index) before and after 3 months of using nebivolol. 88.5% of the patients were male; their mean age was 49.7 ± 9.3 years and most of them were overweight (29.6 ± 3.1 kg/m2) with large abdominal waist (102.1 ± 7.2 cm). There were significant decreases in peripheral systolic BP (P = 0.0020), diastolic BP (P = 0.0049), HR (P < 0.0001) and central BP (129.9 ± 12.3 versus 122.3 ± 10.3 mmHg; P = 0.0083) after treatment, in comparison with the baseline values. There was no statistical difference in the augmentation index or in the biochemical parameters, from before to after the treatment. Nebivolol use seems to be associated with significant reduction of central BP in stage I hypertensive patients, in addition to reductions in brachial systolic and diastolic BP.